evofosfamide versus ifosfamide patient selection in soft tissue sarcoma
Published 8 years ago • 1.4K plays • Length 5:57Download video MP4
Download video MP3
Similar videos
-
4:05
benefits of adjuvant chemo for soft tissue sarcoma patients
-
8:14
chemotherapy toxicity considerations in soft tissue sarcoma
-
8:17
chemotherapy sensitivity in soft tissue sarcoma
-
8:15
subtyping in soft tissue sarcoma: the palette study
-
3:28
local control in metastatic soft tissue sarcoma
-
5:53
ongoing management decisions in soft tissue sarcoma
-
5:46
future directions in soft tissue sarcoma
-
7:42
challenges in treating soft tissue sarcomas in younger populations
-
3:04
disease state advanced soft tissue sarcoma
-
1:04
dr. philip on treatment challenges for patients with soft tissue sarcoma
-
7:01
eribulin in advanced soft tissue sarcoma
-
6:34
multidisciplinary assessment of soft tissue sarcomas
-
7:29
early data with olaratumab in soft tissue sarcoma
-
1:34
the impact and long-term potential of olaratumab in soft tissue sarcoma
-
8:20
trabectedin in soft tissue sarcoma
-
6:57
maestro: phase iii study of evofosfamide (evo) in combination with gemcitabine...
-
5:50
phase iii assessment of topotecan, cyclophosphamide and high-dose ifosfamide in reecur
-
1:17
dr. tap on olaratumab in patients with soft tissue sarcoma
-
4:10
advanced soft tissue sarcoma—incidence and subtypes